Piotr Marek Swiderski

This inventor holds 24 USPTO granted patents and 11 published patent applications, plus 1 CIPO patent and 2 EPO patents, primarily in Oligonucleotide Therapeutics. Top assignees: Beckman Research Institute, City of Hope, The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 1998-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Piotr Marek Swiderski. Retrieved from https://idiyas.com/inventor/piotr-marek-swiderski

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 24 (Patent Applications = 11)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 2 (Patent Applications = 5)

Average Co-Inventor Count = 2.9

ph-index = 4

Forward Citations = 83(Granted Patents)

Location History:

San Dimas, CA (US) (1998 - 2024)
Duarte, CA (US) (2024)

Company Filing History:

22 out of 692

Beckman Research Institute, City of Hope

patents

2 out of 3,696

The United States of America, as Represented by the Secretary, Department of Health and Human Services

patents

Years Active: 1998-2026

Loading Chart...

Areas of Expertise:

MicroRNA

Therapeutic Agent

Cell Penetrating Conjugates

Oligonucleotide

Proteolysis Targeting Chimera

Bispecific Aptamer

CTLA-4 Aptamer

Cancer Treatment

Multivalent Assemblies

STAT3 Inhibitors

Phosphorothioated Oligodeoxynucleotide

Chimeric DNA/RNA

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12655429 - MICRORNA AS A THERAPEUTIC AGENT (2026-06-16),

2. 12521445 - CELL PENETRATING CONJUGATES AND METHODS OF USE THEREOF (2026-01-13),

3. 12404509 - Oligonucleotide-based proteolysis targeting chimera (2025-09-02),

4. 12227745 - Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof (2025-02-18),

5. 12138279 - Bi specific aptamer (2024-11-12),

6. 12043673 - Complementary RNA linked bispecific T-cell engaging antibodies (2024-07-23),

7. 11912995 - CTLA-4 aptamer conjugates (2024-02-27),

8. 11591596 - Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof (2023-02-28),

9. 11535847 - Multivalent oligonucleotide assemblies (2022-12-27),

10. 11464865 - Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof (2022-10-11),

11. 11208654 - Methods and compositions for the treatment of cancer or other diseases (2021-12-28),

12. 10967070 - Cell penetrating conjugates and methods of use thereof (2021-04-06),

13. 10829765 - STAT3 inhibitors and uses thereof (2020-11-10),

14. 10801026 - Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof (2020-10-13),

15. 10758624 - Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof (2020-09-01),

Title: Innovations and Contributions of Piotr Marek Swiderski in Biotechnology

Introduction

Piotr Marek Swiderski, a resident of San Dimas, CA, is a prominent inventor in the field of biotechnology, renowned for his remarkable contributions and innovative approaches. With a portfolio of 21 patents, he has made significant strides in developing advanced therapeutic techniques that harness the potential of nucleic acids and aptamers.

Latest Patents

Among his latest innovations, one of his noteworthy patents includes "Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof." This invention relates to a compound comprising a nucleic acid sequence that is conjugated to an anti-microRNA or a microRNA-mimic. Additionally, it introduces a method for treating specific diseases by suppressing microRNA activity through the disclosed compound or composition. Another important patent is centered around a "Bi-specific aptamer," which pertains to the creation of aptamers capable of binding a tumor cell antigen and an immune cell surface protein, potentially revolutionizing cancer treatment strategies.

Career Highlights

Piotr is currently affiliated with City of Hope, a leading research and treatment institution, where he utilizes his expertise in biotechnology to advance the field. His career is marked by a focus on developing innovative therapies that have the potential to improve patient outcomes significantly.

Collaborations

Throughout his career, Piotr has collaborated with other esteemed professionals, including Marcin Tomasz Kortylewski and Hua Yu. These partnerships have fostered an environment of innovation, leading to the development of groundbreaking treatments and research breakthroughs.

Conclusion

With an impressive array of patents and a strong commitment to advancing biotechnology, Piotr Marek Swiderski stands out as a key contributor in the field. His innovative work in developing nucleic acid-based compounds and bi-specific aptamers not only showcases his expertise but also holds promise for significant advancements in therapeutic treatments and patient care.

Profile summary based on public USPTO records.